health catalyst inc - HCAT

HCAT

Close Chg Chg %
2.38 0.04 1.68%

Closed Market

2.42

+0.04 (1.68%)

Volume: 287.83K

Last Updated:

Dec 26, 2025, 4:00 PM EDT

Company Overview: health catalyst inc - HCAT

HCAT Key Data

Open

$2.39

Day Range

2.36 - 2.48

52 Week Range

2.02 - 7.65

Market Cap

$168.34M

Shares Outstanding

70.73M

Public Float

62.38M

Beta

1.73

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.58

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

631.29K

 

HCAT Performance

1 Week
 
2.98%
 
1 Month
 
-19.06%
 
3 Months
 
-13.57%
 
1 Year
 
-65.82%
 
5 Years
 
-94.61%
 

HCAT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 11
Full Ratings ➔

About health catalyst inc - HCAT

Health Catalyst, Inc. engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers. The company was founded by Steven C. Barlow and Thomas D. Burton in 2008 and is headquartered in South Jordan, UT.

HCAT At a Glance

Health Catalyst, Inc.
10897 South River Front Parkway
South Jordan, Utah 84095
Phone 1-801-708-6800 Revenue 306.58M
Industry Packaged Software Net Income -69,502,000.00
Sector Technology Services 2024 Sales Growth 3.597%
Fiscal Year-end 12 / 2025 Employees 1,500
View SEC Filings

HCAT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.388
Price to Book Ratio 1.24
Price to Cash Flow Ratio 29.23
Enterprise Value to EBITDA -32.708
Enterprise Value to Sales 1.421
Total Debt to Enterprise Value 0.923

HCAT Efficiency

Revenue/Employee 204,389.333
Income Per Employee -46,334.667
Receivables Turnover 5.306
Total Asset Turnover 0.393

HCAT Liquidity

Current Ratio 1.423
Quick Ratio 1.423
Cash Ratio 1.203

HCAT Profitability

Gross Margin 32.735
Operating Margin -17.859
Pretax Margin -22.561
Net Margin -22.67
Return on Assets -8.906
Return on Equity -18.986
Return on Total Capital -9.056
Return on Invested Capital -12.137

HCAT Capital Structure

Total Debt to Total Equity 110.147
Total Debt to Total Capital 52.414
Total Debt to Total Assets 46.833
Long-Term Debt to Equity 45.856
Long-Term Debt to Total Capital 21.821
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Health Catalyst Inc - HCAT

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
241.93M 276.24M 295.94M 306.58M
Sales Growth
+28.11% +14.18% +7.13% +3.60%
Cost of Goods Sold (COGS) incl D&A
161.69M 188.97M 203.34M 206.22M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
41.11M 51.53M 45.21M 41.43M
Depreciation
9.09M 14.33M 15.59M 12.80M
Amortization of Intangibles
32.03M 37.20M 29.62M 28.63M
COGS Growth
+38.43% +16.87% +7.60% +1.42%
Gross Income
80.23M 87.26M 92.60M 100.36M
Gross Income Growth
+11.37% +8.76% +6.12% +8.38%
Gross Profit Margin
+33.16% +31.59% +31.29% +32.74%
2021 2022 2023 2024 5-year trend
SG&A Expense
194.15M 210.15M 178.36M 155.12M
Research & Development
61.83M 69.22M 68.50M 56.80M
Other SG&A
132.32M 140.93M 109.86M 98.31M
SGA Growth
+28.23% +8.24% -15.13% -13.03%
Other Operating Expense
- - - -
-
Unusual Expense
29.73M 17.12M 41.14M 15.05M
EBIT after Unusual Expense
(143.65M) (140.00M) (126.90M) (69.81M)
Non Operating Income/Expense
855.00K 5.56M 16.39M 17.72M
Non-Operating Interest Income
831.00K 5.69M 16.39M 17.98M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
17.31M 7.24M 7.29M 17.09M
Interest Expense Growth
+26.22% -58.19% +0.66% +134.47%
Gross Interest Expense
17.31M 7.24M 7.29M 17.09M
Interest Capitalized
- - - -
-
Pretax Income
(160.11M) (141.68M) (117.79M) (69.17M)
Pretax Income Growth
-37.77% +11.51% +16.86% +41.28%
Pretax Margin
-66.18% -51.29% -39.80% -22.56%
Income Tax
(6.90M) (4.28M) 356.00K 333.00K
Income Tax - Current - Domestic
209.00K 200.00K 144.00K 194.00K
Income Tax - Current - Foreign
27.00K 43.00K 204.00K 62.00K
Income Tax - Deferred - Domestic
(7.13M) (4.52M) 9.00K 73.00K
Income Tax - Deferred - Foreign
- (1.00K) (1.00K) 4.00K
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(153.21M) (137.40M) (118.15M) (69.50M)
Minority Interest Expense
- - - -
-
Net Income
(153.21M) (137.40M) (118.15M) (69.50M)
Net Income Growth
-33.21% +10.32% +14.01% +41.17%
Net Margin Growth
-63.33% -49.74% -39.92% -22.67%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(153.21M) (137.40M) (118.15M) (69.50M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(153.21M) (137.40M) (118.15M) (69.50M)
EPS (Basic)
-3.2258 -2.5577 -2.0941 -1.1548
EPS (Basic) Growth
-10.90% +20.71% +18.13% +44.85%
Basic Shares Outstanding
47.49M 53.72M 56.42M 60.18M
EPS (Diluted)
-3.2258 -2.6271 -2.0941 -1.1548
EPS (Diluted) Growth
-10.90% +18.56% +20.29% +44.85%
Diluted Shares Outstanding
47.49M 54.08M 56.42M 60.18M
EBITDA
(72.81M) (71.36M) (40.55M) (13.32M)
EBITDA Growth
-29.23% +1.99% +43.18% +67.14%
EBITDA Margin
-30.10% -25.83% -13.70% -4.35%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 3.944
Number of Ratings 11 Current Quarters Estimate 0.099
FY Report Date 12 / 2025 Current Year's Estimate 0.204
Last Quarter’s Earnings 0.06 Median PE on CY Estimate N/A
Year Ago Earnings 0.28 Next Fiscal Year Estimate 0.36
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 9 6 9 9
Mean Estimate 0.10 0.08 0.20 0.36
High Estimates 0.15 0.15 0.25 0.62
Low Estimate 0.07 0.03 0.18 0.21
Coefficient of Variance 22.76 50.11 10.41 33.68

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 4
OVERWEIGHT 0 0 0
HOLD 7 7 8
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Health Catalyst Inc - HCAT

Date Name Shares Transaction Value
Apr 8, 2025 Dan LeSueur Chief Operating Officer 211,041 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.15 per share 875,820.15
Mar 11, 2025 Benjamin Landry General Counsel 160,437 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.55 per share 729,988.35
Feb 21, 2025 Linda Llewelyn Chief People Officer 85,819 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.43 per share 465,997.17

Health Catalyst Inc in the News